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FE C282Y homozygotes have reduced low-density
ipoprotein cholesterol: the Atherosclerosis Risk in
ommunities (ARIC) Study
AMES S. PANKOW, ERIC BOERWINKLE, PAUL C. ADAMS, ELISEO GUALLAR,
ATHERINE LEIENDECKER-FOSTER, JASON ROGOWSKI, and JOHN H. ECKFELDT
INNEAPOLIS, MINN; HOUSTON, TEX; LONDON, ONTARIO; AND BALTIMORE, MD
Recent studies have raised questions about the long-term health risks for individuals
with mutations in the HFE gene, although previous studies may have been plagued by
selection bias or lack of population-based comparison groups. We examined cardio-
vascular disease risk factors and iron and liver biomarkers, as well as morbidity and
mortality associated with the C282Y and H63D variants of HFE in the Atherosclerosis Risk
in Communities (ARIC) study, which is a population-based cohort of nearly 16,000 U.S.
white and blackmenandwomenwhowere 45–64 years old at baseline. Subjects were
followed for an average of 15 years for death, incident coronary heart disease, stroke,
and heart failure, and an average of 8 years for incident diabetes. The prevalence of
C282Y homozygosity was 0.42% (45/10,800) in whites, which is similar to other North
American population-based studies. C282Y homozygotes had significantly lower
mean low-density lipoprotein (LDL) cholesterol and fibrinogen as well as higher mean
levels of iron (ferritin, transferrin saturation) and liver biomarkers (alanine aminotrans-
ferase, Hepascore) compared with HFEwild-type subjects. Rates of all-causemortality,
cardiovascular disease, and diabetes were similar across HFE genotypes. These pro-
spective, population-based data indicate higher serum iron indices and possible mild
liver dysfunction or disease in some C282Y homozygotes, but they provide little evi-
dence that HFE C282Y or H63D mutations are related to all-cause mortality, cardiovas-
cular disease, or diabetes. Reduced LDL in C282Y homozygotes may be because of
effects of excess iron on cholesterol metabolism and lipoprotein formation in the liver.
(Translational Research 2008;152:3–10)
Abbreviations: ARIC  Atherosclerosis Risk in Communities; CHD  coronary heart disease; CI
 confidence interval; HDL  high-density lipoprotein; HR  hazard ratio; LDL  low-density
lipoprotein; MI  myocardial infarction
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that may lead to excessive iron accumulation in
various body tissues. Shortly after the discovery
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4 Pankow et al July 2008essive body iron deposition and clinically overt disease,
ost notably in the liver, heart, pancreas, joints, or pitu-
tary.2 However, large screening studies from Norway3
nd southern California4 showed that the prevalence of
linical disease in target organs was similar in C282Y
omozygotes compared with subjects without the muta-
ion, and none of the 23 homozygotes in another popula-
ion-based cohort developed clinical signs or symptoms
hat suggested hereditary hemochromatosis during 25
ears of follow-up.5 Some of these studies have been
riticized for a failure to ascertain subclinical disease, such
s liver fibrosis.6 Additional concerns have been raised
bout the possibility of selection bias, as individuals who
lready had clinical manifestations were unlikely to be
creened or may have died prematurely,7 although at least
n some studies, evaluation of HardyWeinberg equilib-
ium found no deficit in the anticipated number of C282Y
omozygotes.8
Although it is unlikely that most C282Y homozy-
otes eventually develop serious morbidity and early
ortality, as was suggested less than a decade ago,2 the
linical significance of HFE mutations remains uncer-
ain.9 The U.S. Preventive Services Task Force recently
oncluded that there is “insufficient evidence to confi-
ently project the impact of, or estimate the benefit
rom, widespread or high-risk genetic screening for
ereditary hemochromatosis.”9 Because the health ben-
fits of screening for a disease depend largely on the
AT A GLANCE COMMENTARY
Background
Although it is unlikely that most C282Y homozy-
gotes eventually develop serious morbidity and early
mortality, the clinical significance of HFE mutations
remains uncertain. A recent systematic review by the
U.S. Preventive Services Task Force noted that the
many previous studies of HFE may have been
plagued by selection bias or lack of population-based
comparison groups.
Translational Significance
In the population-based Atherosclerosis Risk in
Communities (ARIC) study, C282Y homozygotes
had significantly higher levels of serum iron mea-
sures and biomarkers of liver function, but little
evidence suggested that HFE genotypes are related
to all-cause mortality, cardiovascular disease, or di-
abetes. These data do not support population screen-
ing for HFE mutations.atural history, to determine the incidence of clinically Fignificant morbidity or mortality related to HFE mu-
ations is highly relevant. In the current report, we
valuated morbidity and mortality associated with the
282Y and H63D mutations of HFE in a U.S. cohort
scertained using carefully designed and executed pop-
lation-based sampling techniques.
ETHODS
Study population. In 1987–1989, the Atherosclerosis Risk
n Communities (ARIC) Study enrolled 15,792 subjects aged
5–64 years in 4 U.S. locations: Forsyth County, NC; Jack-
on, Miss; 7 northwestern suburbs of Minneapolis, Minn; and
ashington County, Md.10 Black residents were over-
ampled as part of the area-probability sampling of Forsyth
ounty, NC, whereas enrollment at the Jackson, Miss, site
as restricted to black residents. Eligible residents were in-
ited to participate in a baseline clinical examination (visit 1)
nd 3 subsequent follow-up examinations approximately 3
ears apart (visits 2–4). For the current analysis, we excluded
8 participants who were not white or black, 43 participants
ho did not provide consent for genetic studies, and 1216
articipants with missing data for either the C282Y or H63D
ariants, which left 14,485 subjects (10,800 whites and 3685
lacks) available for analysis. The research was carried out
ccording to the principles of the Declaration of Helsinki.
nstitutional Review Boards at each study institution provided
pproval, and all participants gave informed consent.
Baseline data collection. At baseline, interviewers col-
ected information on menopausal status, smoking status, and
revious diagnoses, which included cancer.10 Fasting lipids,
lucose, insulin, and fibrinogen were measured at a central
aboratory using methods described previously,11-13 and he-
atology was performed at local laboratories. Prevalent cor-
nary heart disease was defined as a self-reported history of a
hysician-diagnosed heart attack, evidence of an old myocar-
ial infarction (MI) by electrocardiogram based on the Min-
esota codes, or reported history of coronary revasculariza-
ion. Prevalent stroke was defined as a reported stroke
iagnosed by a physician. Prevalent diabetes was defined as
eported physician diagnosis, use of antidiabetes medications,
asting (8 hr postprandial) serum glucose of 7 mmol/L (140
g/dL) or more, or nonfasting glucose of 11.1 mmol/L (200
g/dL) or more. Prevalent heart failure was defined as re-
orted current intake of heart failure medication at visit 1 or
vidence of manifest heart failure defined by the Gothenburg
riteria stage 3.14,15 Carotid intimal-medial thickness was
easured by B-mode ultrasound16,17 and the mean intimal-
edial thickness across 3 segments (internal carotid, bifurca-
ion, and common carotid) was used in analysis. History of
atigue was assessed at visit 2 by the question, “Do you often
eel tired?” History of arthritis was assessed at visit 4 by the
uestion, “Has a doctor ever told you that you have arthritis?”
FE variants were typed at the ARIC DNA Laboratory,
niversity of Texas Health Science Center at Houston, using
standard Taqman method. All C282Y homozgyotes
C282Y/C282Y) were verified at CLIA-certified Clinical
aboratories of the University of Minnesota Medical Center,
airview, using a restriction endonuclease method.1
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Volume 152, Number 1 Pankow et al 5Iron and liver biomarkers. Because of limited resources,
ron and liver biomarkers were measured only in C282Y
omozygotes, and a comparison group of 48 wild-type sub-
ects randomly selected from white ARIC controls in the
ongitudinal Investigation of Thromboembolism Etiology
tudy,18 frequency matched to C282Y homozygotes by age
roup (45–54, 55–64, or 65–74 years) at the time of veni-
uncture. When available, serum from the most recent full
ohort examination (visit 4, 1996–1998) was used; serum
rom visit 2 (n  8) or visit 1 (n  3) was used for a few
ubjects, and it was unavailable for all visits in 1 C282Y
omozygote. Transferrin saturation was measured using an
utomated spectrophotometric measurement of iron and un-
aturated iron-binding capacity on a Roche/Hitachi 911 ana-
yzer using commercially available reagents (Roche Diagnos-
ics/Boehringer Mannheim Corp., Indianapolis, Ind). Ferritin,
lanine aminotransferase, -glutamyltransferase, and total
ilirubin were measured using the same equipment and com-
ercially available assays from Roche Diagnostics. Alpha-2-
acroglobulin was assayed using the Immage analyzer and
ommercially available reagents (Beckman-Coulter, Inc.,
rea, Calif), and hyaluronic acid was measured using an
nzyme-linked immunosorbent assay kit (Corgenix Inc.,
estminster, Colo). Coefficients of variation for all assays
ere less than 5.4% except ferritin and unsaturated iron
inding capacity, which were 9.9% and 8.4%, respectively.
o assess liver fibrosis, we used a predictive model (Hepas-
ore) based on bilirubin, -glutamyltransferase, hyaluronic
cid, 2-macroglobulin, age, and sex previously validated in
ubjects with chronic hepatitis C infection.19
Morbidity and mortality follow-up. Liver disease was as-
essed at visit 3 by the question, “Has a doctor ever said you
ad cirrhosis or another chronic liver disease?” and searches
f underlying and contributing causes of death (ICD-9 570-
73 or 155; ICD-10 K7 or C22) and hospital discharge
iagnoses (ICD-9 CM 570-573 or 155). Clinical diagnosis of
emochromatosis was ascertained as a discharge diagnosis of
emochromatosis (ICD-9 CM 275.0). All-cause mortality
as ascertained by reviews of death certificates, annual fol-
ow-up interviews, hospital charts, and other means. The
etails on quality assurance for ascertainment and classifica-
ion of coronary heart disease (CHD) and stroke events have
een published elsewhere.10,20,21 Incident CHD events were
efined as a validated definite or probable hospitalized MI,
efinite CHD death, unrecognized MI defined by ARIC elec-
rocardiogram readings, or coronary revascularization. Inci-
ent ischemic stroke was defined as validated definite or
robable hospitalized embolic or thrombotic brain infarctions.
ncident heart failure was defined as a hospital discharge
iagnosis coded with heart failure at any position (ICD-9 CM
able I. HFE C282Y and H63D genotype frequencie
C282Y/C282Y C282Y/H63D
hites, N (%) 45 (0.4) 193 (1.8)
lacks, N (%) 1 (0.03) 3 (0.1)28) or death with heart failure coded as the underlying cause tf death (ICD-9 428; ICD-10 I50).22 Subjects were defined as
aving incident diabetes if they met any criteria listed above
or prevalent diabetes at any of the follow-up visits with date
f diagnosis interpolated between visits.23
Statistical analysis. We tested the C282Y and H63D vari-
nts separately for HardyWeinberg equilibrium using 2
oodness-of-fit tests. Pairwise differences in baseline charac-
eristics between each combined C282Y and H63D genotype
roup and a common reference group of subjects wild type
or both variants were tested by analysis of variance (contin-
ous measures) or logistic regression (dichotomous mea-
ures) as implemented in SAS (version 9.1; SAS Institute
nc., Cary, NC). For iron and liver biomarkers, differences
etween C282Y homozygotes and wild-type subjects were
ested by analysis of covariance, adjusting for age (matching
ariable) and sex. Triglycerides, insulin, ferritin, bilirubin,
-glutamyltransferase, hyaluronic acid, and alanine amino-
ransferase were log-transformed before analysis. For longi-
udinal outcomes, we calculated person-years at risk for each
articipant as the time between the baseline examination date
nd the last date of follow-up (eg, December 31, 2004 for all
utcomes except diabetes), date of loss to follow-up, date of
eath, or date of disease diagnosis. We used the Epitab
rocedure in STATA (release 8; StataCorp, College Station,
ex) to estimate rate ratios and exact confidence intervals.
ESULTS
Genotype frequencies for C282Y and H63D did
ot deviate statistically from those expected under
ardyWeinberg equilibrium in whites or blacks (P
0.05). Among whites, there were slightly more
282Y homozygotes (n  45) than expected under
ardyWeinberg equilibrium conditions (n  43.3).
nly 4 black subjects were either C282Y homozy-
otes or C282Y/H63D compound heterozygotes (Ta-
le I), which thereby precluded detailed analyses of
hose genotypes. All additional analyses were re-
tricted to whites.
Mean low-density lipoprotein (LDL) cholesterol and
brinogen levels at baseline were substantially lower
mong C282Y homozygotes compared with wild-type
ubjects (Table II). Similar patterns were observed for
DL during follow-up: mean levels were 0.31 mmol/L
12 mg/dL; P  0.06), 0.44 mmol/L (17 mg/dL; P 
.007), and 0.47 mmol/L (18 mg/dL; P 0.003) lower in
282Y homozygotes at visits 2, 3, and 4, respectively. No
djustment was made for lipid-lowering medications in
3D C282Y/ H63D/ /
.4) 1084 (10.0) 2453 (22.7) 6768 (62.7)
.1) 100 (2.7) 189 (5.1) 3389 (92.0)s
H63D/H6
257 (2hese analyses. At visit 4, self-reported use of lipid-low-
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9
i
h
p
m
r
t
e
u
w
w
b
h
t
T
A
G
P
C
B
L
H
T
F
F
F
H
H
W
P
H
C
H
H
H
N
A
*
†
‡
§
T
F
T
T
U
T
H
A
*
†
Translational Research
6 Pankow et al July 2008ring medications was nearly twice as common among
ild-type subjects than C282Y homozygotes (16% vs
%), although this difference was not statistically signif-
cant. At baseline, mean hematocrit and hemoglobin were
igher in carriers of the C282Y or H63D mutations com-
ared with wild-type subjects, although for C282Y ho-
ozygotes, differences were not statistically significant.
Among C282Y homozygotes, 11 (25%) had fer-
able II. Baseline characteristics (Means (standard
Characteristic
C282Y/C282Y
(N  45)
C282Y/H63D
(N  193)
ge (years) 53.4 (0.9) 54.1 (0.4)
ender (% men) 47 40
ost-menopausal, women (%) 55 66
urrent smoking (%) 18 30
ody mass index (kg/m2) 26.5 (0.7) 27.5 (0.3)
DL cholesterol (mmol/L) 3.18 (0.15) 3.58 (0.07)
DL cholesterol (mmol/L) 1.41 (0.06) 1.30 (0.03)
riglycerides (mmol/L)* 1.18 (0.80-1.94) 1.37 (0.98-1.91
asting glucose (mmol/L)† 5.46 (0.08) 5.46 (0.04)
asting insulin (pmol/L)† 65.2 (8.4) 75.9 (4.1)
ibrinogen (g/L) 2.79 (0.09) 3.05 (0.04)
ematocrit (volume fraction) 0.425 (0.006) 0.431 (0.003)
emoglobin (mmol/L) 2.218 (0.030) 2.250 (0.015)
hite cell count (109 cells/L) 6.02 (0.30) 6.52 (0.14)
latelet count (109 cells/L) 243 (11) 252 (6)
ypertension (%) 22 33
arotid IMT (mm) 0.724 (0.031) 0.716 (0.015)
istory of cancer (%) 9.1 5.7
istory of fatigue (%)‡ 40 49
istory of arthritis (%)§ 29 32
ote: Estimates listed in bold are significantly different (p  0.05) c
bbreviation: IMT, intimal-medial thickness
Medians and interquartile ranges are shown
Among subjects without diabetes
Measured at visit 2
Measured at visit 4
able III. Serum iron and liver biomarkers by HFE C2
Biomarker
C282Y/C2
Median I
erritin (g/L)† 741
ransferrin saturation (fraction saturation) 0.77
otal iron (mol/L) 33.8
nsaturated iron binding capacity (mol/L) 10.9
otal iron binding capacity (mol/L) 43.7
epascore† 0.10
Bilirubin (mol/L)† 6.8
Gamma glutamyltransferase (U/L)† 20
Hyaluronic acid (g/L)† 24
2-macroglobulin (g/L) 1.9
lanine aminotransferase (U/L)† 20
Obtained from linear regression models adjusted for age and se
Log-transformed for linear regression analysisitin levels greater than 1000 g/L, whereas none of phe 48 age-matched wild-type subjects had levels that
xceeded this cutpoint. Mean ferritin, transferrin sat-
ration, and total iron were significantly higher,
hereas unsaturated and total iron-binding capacities
ere significantly lower in C282Y homozygotes (Ta-
le III). The Hepascore index was significantly
igher in C282Y homozygotes (P  0.003), although
here were only small differences for individual com-
or percentages) by HFE genotype, ARIC whites
D/H63D
 257)
C282Y/
(N  1084)
H63D/
(N  2453)
/
(N  6768)
(0.4) 54.3 (0.2) 54.4 (0.1) 54.4 (0.1)
49 45 48 48
72 63 65 66
25 25 25 25
(0.3) 27.1 (0.1) 27.1 (0.1) 26.9 (0.1)
(0.06) 3.52 (0.03) 3.56 (0.02) 3.56 (0.01)
(0.03) 1.31 (0.01) 1.30 (0.01) 1.31 (0.01)
(1.05-1.94) 1.33 (0.93-1.88) 1.31 (0.93-1.88) 1.28 (0.93-1.83)
(0.03) 5.45 (0.02) 5.48 (0.01) 5.47 (0.01)
(3.7) 72.6 (1.7) 73.1 (1.2) 72.4 (0.7)
(0.04) 2.97 (0.02) 2.98 (0.01) 2.97 (0.01)
(0.002) 0.424 (0.001) 0.423 (0.001) 0.421 (0.001)
(0.013) 2.205 (0.006) 2.197 (0.004) 2.182 (0.002)
(0.13) 6.27 (0.06) 6.38 (0.04) 6.27 (0.02)
(5) 257 (2) 256 (2) 260 (1)
34 28 29 26
(0.013) 0.722 (0.006) 0.725 (0.004) 0.727 (0.002)
7.4 5.1 6.5 7.2
47 45 45 43
42 41 40 38
d to / subjects
notype, ARIC whites
44) / (N  48)
p-value*ile range Median Interquartile range
1143 157 82-238 0.001
0.95 0.30 0.24-0.35 0.001
38.3 16.1 12.9-19.9 0.001
18.1 40.1 33.5-45.5 0.001
50.8 55.8 51.7-61.4 0.001
0.26 0.08 0.06-0.12 0.003
10.3 6.8 5.1-7.7 0.15
30 20 12-31 0.71
34 19 13-27 0.05
2.3 1.8 1.6-2.2 0.09
29 11 8-14 0.001errors)
H63
(N
54.5
27.3
3.59
1.28
) 1.39
5.50
69.2
3.00
0.426
2.220
6.48
256
0.719
ompare82Y ge
82Y (N 
nterquart
377-
0.62-
27.4-
2.0-
38.8-
0.06-
5.1-
15-
15-
1.6-
14-
xonents of the index, which included bilirubin,
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Volume 152, Number 1 Pankow et al 7-glutamyltransferase, hyaluronic acid, and 2-mac-
oglobulin.
Mean length of follow-up was 15 years for all-cause
ortality, CHD, stroke, and heart failure, and it was 8
ears for diabetes. Rates of all-cause mortality, incident
HD, stroke, heart failure, and diabetes were similar
cross HFE genotypes (Table IV). Five C282Y ho-
ozygotes (11%) had clinical evidence of liver disease
uring follow-up, which included 2 subjects who died
ith an underlying cause of death coded as hepatocel-
ular carcinoma and cholangiocarcinoma, respectively,
subjects with hospital discharge diagnoses that indi-
ated liver disease, and 1 subject who self-reported
iver disease at visit 3. Among wild-type subjects, 3%
ad clinical evidence of liver disease. Prior to any
enetic testing as part of this study, 4 C282Y homozy-
otes (9%) had a hospital discharge diagnosis of hemo-
hromatosis during follow-up, whereas only 1 wild-
ype subject (0.01%) had such a diagnosis.
ISCUSSION
We found that genotype frequencies for C282Y and
63D in the population-based ARIC cohort were sim-
lar to those reported for whites and blacks in the
EIRS study,24 the U.S.-representative NHANES III
nvestigation,25 and a health-maintenance organization
n southern California.8 No evidence suggested that
282Y homozygotes had been selectively lost from the
able IV. All-cause mortality and incident disease b
Outcome C282Y/C282Y C282Y/H63D
ll-Cause Mortality
Deaths 7 30
Person-years 704 2,954
Rate per 1000 person-years 9.9 10.2
Rate ratio (Exact 95% CI) 0.97 (0.39-2.00) 0.99 (0.66-1.4
ncident CHD
Cases 6 28
Person-years 670 2,638
Rate per 1000 person-years 9.0 10.6
Rate ratio (Exact 95% CI) 0.96 (0.35-2.10) 1.14 (0.75-1.6
ncident Stroke
Cases 1 11
Person-years 692 2,887
Rate per 1000 person-years 1.4 3.8
Rate ratio (Exact 95% CI) 0.60 (0.01-3.36) 1.58 (0.78-2.8
ncident Heart Failure
Cases 2 16
Person-years 704 2,697
Rate per 1000 person-years 2.8 5.9
Rate ratio (Exact 95% CI) 0.48 (0.06-1.75) 1.01 (0.57-1.6
ncident Diabetes
Cases 3 19
Person-years 299 1,312
Rate per 1000 person-years 10.0 14.5
Rate ratio (Exact 95% CI) 0.81 (0.17-2.39) 1.17 (0.70-1.8opulation by the time subjects were enrolled in the pRIC cohort, which is similar to the findings of Beutler
t al.8 Furthermore, our results indicated similar rates of
ll-cause mortality across all HFE genotypes over an
verage of 15 years of follow-up. Consistent with our
esults, cross-sectional studies in Finland,26 the Neth-
rlands,27 and France28 did not find lower frequencies
f the C282Y mutation in older age groups, as might be
xpected if the mutation is an important cause of death.
imilarly, the Melbourne Collaborative Cohort Study
ound that HFE genotypes were unrelated to all-cause
ortality over 11.4 years of follow-up in 29,676 sub-
ects of northern European ancestry.6
C282Y homozygotes had a more favorable lipid pro-
le, with mean LDL-cholesterol concentrations lower
han wild-type subjects. To our knowledge, no previous
tudies have reported an association between C282Y
omozygosity and LDL cholesterol. Interestingly, 1
tudy found that self-reported cholesterol problems
ere 3 to 5 times more frequent in wild-type subjects
ompared with C282Y/C282Y subjects.29 Although
his finding was considered likely caused by chance,29
ur results are consistent with less-frequent use of
holesterol-lowering drugs among C282Y homozy-
otes. The effect of the HFE C282Y mutation on mean
DL levels in the ARIC study (0.38 mmol/L or 15
g/dL) is similar in magnitude to the range of effects
n LDL (0.05–0.23 mmol/L or 2–9 mg/dL per allele)
or the 11 most significant single nucleotide polymor-
enotype, ARIC whites
H63D/H63D C282Y/ H63D/ /
45 174 399 1066
3,900 16,717 37,599 103,755
11.5 10.4 10.6 10.3
12 (0.81-1.51) 1.01 (0.86-1.19) 1.03 (0.92-1.16) 1.00 (ref)
31 145 308 860
3,463 14,820 33,191 92,218
9.0 9.8 9.3 9.3
96 (0.65-1.37) 1.05 (0.87-1.25) 1.00 (0.87-1.13) 1.00 (ref)
11 50 93 245
3,799 16,215 36,680 101,316
2.9 3.1 2.5 2.4
20 (0.59-2.18) 1.27 (0.92-1.73) 1.05 (0.82-1.34) 1.00 (ref)
23 100 224 564
3,658 15,384 34,934 96,001
6.3 6.5 6.4 5.9
07 (0.67-1.62) 1.11 (0.89-1.37) 1.09 (0.93-1.28) 1.00 (ref)
20 87 241 566
1,583 7,400 16,397 45,805
12.6 11.8 14.7 12.4
02 (0.62-1.59) 0.95 (0.75-1.19) 1.19 (1.02-1.39) 1.00 (ref)y HFE g
2) 1.
6) 0.
9) 1.
5) 1.hisms, which include those near the APOE/C1/C4,
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8 Pankow et al July 2008DLR, APOB, and PCSK9 genes, in a combined anal-
sis of 3 recent genome-wide association studies from
urope.30 However, the frequency of the C282Y/
282Y genotype is only 0.4% to 0.5% in populations of
uropean ancestry, which makes it unlikely that these
enome-wide association studies of LDL were suffi-
iently powered to detect an effect of a rare variant such
s HFE.
Experimental iron overload in rats has been found to
ower LDL and raise high-density lipoprotein (HDL).31
xcess iron could affect cholesterol metabolism by
ausing increased intracellular oxidative stress, mem-
rane peroxidation, and altered activity of liver en-
ymes involved in cholesterol metabolism and lipopro-
ein formation.31 Alternatively, differences in
holesterol levels could reflect long-term liver damage
aused by iron overload in C282Y homozygotes.
mong patients with chronic hepatitis C, total choles-
erol levels have been found to be 0.31–0.41 mmol/L
12–16 mg/dL) lower, on average, among those with
ignificant liver fibrosis compared with those with no
ignificant fibrosis, possibly because of reduced choles-
erol synthesis in more advanced forms of liver dis-
ase.32,33
According to previously published results from the
RIC Study,34 CHD risk was increased by about 40%
or every 1-mmol/L increment in LDL cholesterol.
herefore, the observed difference in LDL concentra-
ion between wild-type subjects and C282Y homozy-
otes (ie, approximately 0.4 mmol/L) would predict a
6% lower rate of incident CHD among C282Y ho-
ozygotes. However, we did not find a statistically
ignificant association between either HFE C282Y or
63D mutations and risk of coronary heart disease; this
nding is consistent with other prospective studies.35-38
ven large cohort studies such as our own are unlikely
o detect small reductions in CHD risk possibly medi-
ted by lower LDL concentrations because of the rel-
tively small number of C282Y homozygotes available
or follow-up. In contrast to our results, an earlier
ase-cohort analysis from the ARIC study39 found that
282Y heterozygotes had a significantly increased risk
f CHD after adjustment for traditional risk factors
hazard ratio (HR) 2.7; 95% confidence interval (CI):
.2–6.1], but our results do not corroborate that previ-
us analysis. In fully adjusted models identical to those
sed in the earlier report, the HRs for incident CHD in
he current analysis were 0.97 (95% CI: 0.63–1.5) for
vents ascertained through calendar year 1991, the last
ate of follow-up in the earlier report, and 1.03 (95%
I: 0.88–1.2) when follow-up was extended through
004. The discrepancy between the earlier report and
he present analysis is likely because C282Y carriers
ere underrepresented as a result of random error in- sroduced when only a sample of the cohort was selected
or the earlier study. In the earlier report, the frequency
f the HFE C282Y mutation in the ARIC cohort was
stimated to be 6.1% based on a cohort random sample
f only 535 subjects39; in the current analysis, the
requency of the C282Y mutation was found to be
ubstantially higher (9.7%) in 10,800 white subjects
rom the full cohort.
Of the 6 genotype groups, wild-type subjects had the
owest mean hematocrit and hemoglobin values and the
ighest mean platelet count. Similar patterns have been
eported previously.40,41 As expected, C282Y homozy-
otes had higher levels of biomarkers of liver dysfunc-
ion and disease, which include alanine aminotransfer-
se and the Hepascore index. Hepascore provides an
rea under the curve of 0.76–0.82 for significant biopsy-
etermined liver fibrosis among patients with chronic
epatitis C infection.19,42,43 Although only a few sub-
ects had Hepascore values consistent with significant
brosis, differences between C282Y homozygotes and
ild-type subjects may reflect more subtle or early
ndications of liver damage. Beutler et al4 similarly
ound that plasma collagen IV concentrations, another
arker of mild hepatic fibrosis, were significantly
igher in homozygotes compared with wild-type sub-
ects.
Strengths of the current study include its large sam-
le size, extensive follow-up, and population-based
ampling that provides inference to the general popu-
ation. A systematic review by the U.S. Preventive
ervices Task Force noted that the many previous stud-
es of HFE may have been plagued by selection bias or
ack of population-based comparison groups.9 The
RIC cohort was enrolled nearly 10 years before the
iscovery of HFE, which makes it unlikely subjects had
een previously screened for mutations or that their
articipation was related to knowledge of their geno-
ype. Limitations include the limited number of C282Y
omozygotes and the small number of controls tested
or iron and liver biomarkers; incomplete information
n liver disease, limited to self-report, hospital and
eath records; and an index of liver fibrosis (Hepa-
core) of uncertain validity in the context of hemochro-
atosis. Recent studies found that 5% to 20% of
282Y homozygotes had subclinical disease detected
y biopsy, which includes cirrhosis and hepatic fibro-
is.6,44 In addition, limited information was available
egarding clinical diagnosis of hemochromatosis, and
arkers of iron metabolism were only measured once,
hich thereby provided an incomplete history of iron
tatus. Studies of untreated C282Y homozygotes have
emonstrated substantial short- and long-term intra-
ndividual variability in serum ferritin and transferrin
aturation levels.45,46
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Volume 152, Number 1 Pankow et al 9Speculations. In the ARIC Study, C282Y homozy-
otes had significantly higher levels of serum iron
easures and biomarkers of liver function, but little
vidence was observed to indicate that HFE genotypes
re related to all-cause mortality, cardiovascular dis-
ase, or diabetes. Reduced LDL in C282Y homozy-
otes may be because of effects of excess iron on
holesterol metabolism and lipoprotein formation in the
iver.
The authors thank the staff and participants of the ARIC Study for
heir important contributions.
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